Healthcare Industry News: immunotherapy
News Release - February 26, 2014
Nodality, Inc. Appoints Ralph Snyderman, M.D., to Board of DirectorsSOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Nodality, Inc. announced today the appointment to the Company’s Board of Directors of Ralph Snyderman, M.D., Chancellor Emeritus at Duke University and James B. Duke Professor of Medicine. Dr. Snyderman offers more than 40 years’ experience in diverse roles to improve the nation’s health, with a long-standing commitment to making personalized medicine a reality.
“We are very pleased that Dr. Snyderman will bring to Nodality his long experience and his vision for the future of medicine,” stated Laura Brege, President and Chief Executive Officer. “Ralph has pioneered new approaches to enhancing our health delivery systems that continue to have a profound and enduring impact. His insights will be invaluable to Nodality as we advance our lead programs with broad applications to immunology, oncology, and the intersection of the two, immune-oncology also known as cancer immunotherapy.”
Dr. Snyderman served as Chancellor for Health Affairs and Dean of Duke’s School of Medicine from 1989 to July 2004. During this period, he oversaw the development of the Duke University Health System, one of the most successful integrated academic health systems in the country, and served as its founding President and Chief Executive Officer. He also led the creation of the Duke Clinical Research Institute (DCRI), the largest academic clinical research institute in the world. Prior to joining Duke, Dr. Snyderman held senior positions at Genentech, Inc., including senior vice president of medical research and development, spearheading the development and licensing of important therapeutic products.
Dr. Snyderman served as chair of the Association of American Medical Colleges in 2001-2002 and as president of the Association of American Physicians in 2003-2004. He is a graduate of Washington College in Chestertown, MD, and received his MD degree, magna cum laude, from Downstate Medical Center of the State University of New York. He served his residency in medicine at Duke and conducted research in immunology at the NIH and at Duke where he led the Division of Rheumatology and Immunology.
Dr. Snyderman stated, “I see Nodality as playing a pivotal role in enhancing and transforming the process of pharmaceutical development. I am enthusiastic about doing all I can to enhance Nodality’s ability to collaborate with leading drug developers across diverse areas to help them create therapeutics that can better meet patients’ needs.”
About Single Cell Network Profiling
Single Cell Network Profiling (SCNP) is a proprietary technology originally developed at Stanford University to characterize cell signaling networks in millions of cells at the single cell level. SCNP, by measuring functional signaling networks within and between cells, provides unprecedented insights into diseases that appear molecularly and phenotypically homogeneous with other technologies. This allows Nodality to improve drug development and use through activities that include identifying rare cell subsets, such as drug-resistant cells, revealing epigenetic changes in cells, and perceiving cell-cell interactions in complex disease states. SCNP therefore has broad application to preclinical drug development, clinical drug development, and diagnostic development.
Nodality is a next-generation life sciences company that is advancing drug discovery, therapeutic development, and precision medicine by delivering critical and clinically actionable information to reveal biology, define disease, and improve health. Nodality's unique, innovative, and proprietary platform, Single Cell Network Profiling or SCNP, enables the promise of precision medicine by characterizing disease biology and optimizing of treatment for the disease. Nodality is applying SCNP to immunology diseases including autoimmune diseases and oncology including cancer immunotherapy. Nodality also is developing molecular diagnostics to improve clinical decision-making in cancer and autoimmune diseases, with the lead products targeting treatment management in hematological malignancies. Nodality collaborates with Pharma partners for patient stratification, companion diagnostic development, drug and disease profiling, determination of mechanism of action, mechanism-based competitive differentiation, and biomarker discovery and development. These applications can result in increased probability of success, reduced time for clinical development, and competitive differentiation. Nodality has established multi-year strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB) and Pfizer (PFE) utilizing its SCNP technology to assist the development of several compounds focusing initially on immunology disorders. For more information on Nodality, please visit www.nodalityinc.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.